

Low-Field Multi-Parametric MRI: Opportunities and Challenges

Carri Glide-Hurst, PhD, DABR, FAAPM

Director of Translational Research, Radiation Oncology
Henry Ford Cancer Institute →

Director, Radiation Oncology Physics, Department of Human Oncology,
University of Wisconsin Madison



Disclosures

- Research funding provided by:
 - NIH R01CA204189 (PI: Glide-Hurst)
 - Philips Healthcare
- Collaborations with Modus Medical Devices, ViewRay (unrelated to the current work)
- Research in conjunction with Mark Haacke, PhD et al. (WSU) and sequences are not FDA approved



Multiparametric MRI (mpMRI)

- Noninvasive assessment of patho-physiological processes
- Multiple contrasts provide insight compared to a single parameter
- In prostate, PI-RADS V2 recommends obtaining T2-weighted, DWI, DCE, and optional spectroscopy

PI-RADS™ v2

The recommendations in this document focus only on 3T and 1.5T MRI scanners since they have been the ones used for clinical validation of mpMRI. Prostate mpMRI at lower magnetic field strengths (<1.5T) is not recommended unless adequate peer reviewed clinical validation becomes available.




Clinical Motivation: Low Field Strength

- ✓ Compact/reduced shielding & footprint
- ✓ Lower costs → wider accessibility
(only 1/10th of world population has access to MRI¹?)
- ✓ Less local heating/SAR
- ✓ Reduced susceptibility effects
- ✓ Desirable characteristics: short T1 and long T2* for efficient pulse sequence design

¹<http://data.oecd.org/healthqt/magnetic-resonance-imaging-mri-units.htm>




Opportunities in Interventional and Diagnostic Imaging by Using High-performance Low-Field-Strength MRI



Signal-to-noise ratio–efficient spiral imaging applied for T1-weighted neuroimaging demonstrated in a 23-year-old (axial sections) and a 28-year-old (sagittal sections).

- Eighty-three MRI examinations were performed in 45 study participants by using a custom 0.55-T MRI system that combines low field strength with advanced hardware and imaging methods.
- MRI-guided cardiovascular catheterizations were performed in seven study participants with commercially available metallic guidewires that generated negligible heating during real-time MRI at 0.55 T.

Increased intensity/improved homogeneity



Low-field ViewRay MRIdian MR-Linac




- Split bore 0.35T MR coupled with a 6XFFF linear accelerator
- Dedicated surface coils for patient imaging



MRgRT for Response Prediction

- H&N cancer patient, decreased ADC observed in GTV
- Longitudinal DWI is feasible with the 0.35T ViewRay MRI




MRI pre-RT


Early ADC
map during
RT

ADC change
slope map
throughout RT



MRI 21
months post-
RT – confirm
recurrence



0.35T Co⁶⁰ Response: Rectal Cancer & Sarcoma




Functional diffusion map:
Darkened areas suggest
treatment-resistant subregions




Shaverdian *et al*, BJR, 2017


Yang *et al.*,
Med Phys, 2016



SIM CT



DWI




ADC Map




STAGE mpMRI

- STAGE^[1-4] employs multi-echo GRE acquisitions with optimal echo times and flip angles
- STAGE obtains multi-contrast qualitative images and quantitative data for studying neuro-degenerative diseases
- Fast (5 mins @ 3T, 10 mins @ 0.35T), 3D high resolution protocol using endogenous tissue contrast




T1 and Proton Density Maps



- T1 Map: quantitative T1 mapping detects enhancing tumor earlier. Serial T1 mapping can be used to generate “differential maps”
- Proton Density Map
- Enhanced T1WE: improved GM/WM contrast-to-noise ratio and image homogeneity than conventional T1W





R2*Maps

- R2*Map can reflect oxygenation state of tumors
- R2*Map differentiates between tumor types: GBMs have high R2* values ^[5]

[5] Liu et al., Eur Radiol, 2014



Benchmarking: ISMRM/NIST Phantom

T1 mapping:


- STAGE- 11 acquisitions
- Compare to standard methods:
 - Variable Flip Angle (VFA) at 0.35T: (2°, 5°, 10°, 20°, 25°, 30°) - 5 acquisitions
 - Inversion Recovery (IR)



Proton Density mapping:


- STAGE – 5 acquisitions, single timepoint

Plate 3, PD Spheres:



% water
5% - 100%



Plate 5, T1 Spheres:



T1 values at
22ms – 2000 ms

0.35T Benchmarking

- STAGE PD agrees with expected
- Relative error of VFA T1 and STAGE T1 relative to IR were ~7.0- 10.0%
- Relative error for PD was ~8%




Nejad-Davarani, S et al., Medical Physics, 2020




HFCI Prospective Clinical Trial



- Feasibility trial of 12 patients imaged and treated on the ViewRay 0.35T MR-linac
- All brain diagnoses eligible



- Spatial correlation with conventional 3T diagnostic MRI and clinical outcomes







Potential Applications in Low Field & Future Work

- Low-field mpMRI offers potential to quantify lesion and surrounding normal tissue changes over time
- Phantom benchmarking appears reliable
- Potential to implement in low resource settings or in hybrid MR environments (MR-OR, MR-linac, etc.)
- With a larger cohort, may use quantitative data to correlate to patient outcomes and treatment response assessment

Thank you!

